Equities

Forecasts data is unavailable for this security.

Consensus recommendation

As of Mar 24, 2017, the consensus forecast amongst 32 polled investment analysts covering Novartis AG advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jan 16, 2017. The previous consensus forecast advised that Novartis AG would outperform the market.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy5
Outperform8
Hold16
Underperform3
Sell0

Dividends

In 2016, Novartis AG reported a dividend of 2.70 USD, equaling last years dividend. The 28 analysts covering the company expect dividends of 2.83 USD for the upcoming fiscal year, an increase of 4.67%.
Div growth (TTM)0.25%
More ▼

Earnings history & estimates

On Jan 25, 2017, Novartis AG reported 4th quarter 2016 earnings of 1.11 per share. This result was in line with the consensus of the 14 analysts following the company and exceeded last year's 4th quarter results by 1.83%.
The next earnings announcement is expected on Apr 25, 2017.
Average growth rate+0.68%
Novartis AG reported annual 2016 earnings of 4.71 per share on Jan 25, 2017.
Average growth rate-2.62%
More ▼

Revenue history & estimates

Novartis AG had 4th quarter 2016 revenues of 12.32bn. This missed the 12.37bn consensus estimate of the 12 analysts following the company. This was 1.58% below the prior year's 4th quarter results.
Average growth rate-0.25%
Novartis AG had revenues for the full year 2016 of 48.52bn. This was 1.81% below the prior year's results.
Average growth rate-3.57%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.